BSG and hepatocellular carcinoma: Licartin, a 131I-radioisotope-labeled anti-CD147 monoclonal antibody (metuximab), was approved for hepatocellular carcinoma treatment by the Chinese State Food and Drug Administration (63) and increased the chemosensitivity of pancreatic cancer to gefitinib and gemcitabine (64).